[go: up one dir, main page]

EA201792203A1 - Фармацевтические композиции для комбинированной терапии - Google Patents

Фармацевтические композиции для комбинированной терапии

Info

Publication number
EA201792203A1
EA201792203A1 EA201792203A EA201792203A EA201792203A1 EA 201792203 A1 EA201792203 A1 EA 201792203A1 EA 201792203 A EA201792203 A EA 201792203A EA 201792203 A EA201792203 A EA 201792203A EA 201792203 A1 EA201792203 A1 EA 201792203A1
Authority
EA
Eurasian Patent Office
Prior art keywords
insulin
blood glucose
disease
pharmaceutical composition
application relates
Prior art date
Application number
EA201792203A
Other languages
English (en)
Other versions
EA036757B1 (ru
Inventor
Марк ПРУЗАНСКИ
Лучано Адорини
Original Assignee
Интерсепт Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Интерсепт Фармасьютикалз, Инк. filed Critical Интерсепт Фармасьютикалз, Инк.
Publication of EA201792203A1 publication Critical patent/EA201792203A1/ru
Publication of EA036757B1 publication Critical patent/EA036757B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Заявка относится к фармацевтической композиции, содержащей комбинацию агониста FXR и по меньшей мере одно дополнительное терапевтическое средство, которое снижает уровень глюкозы в крови, стимулирует секрецию инсулина и/или повышает чувствительность к инсулину. Настоящая заявка относится к применению фармацевтической композиции для лечения или предупреждения заболевания или состояния, опосредованных FXR, таких как NAFLD и NASH, заболевания или состояния, связанных с повышенным уровнем глюкозы в крови, уменьшенной секрецией инсулина и/или уменьшенной чувствительностью к инсулину, а именно гипергликемии, диабета, ожирения и инсулинорезистентности, или для уменьшения уровня глюкозы в крови, стимуляции секреции инсулина и/или повышениячувствительности к инсулину.
EA201792203A 2015-04-07 2016-04-06 Фармацевтические композиции для комбинированной терапии EA036757B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562144040P 2015-04-07 2015-04-07
PCT/US2016/026146 WO2016164413A1 (en) 2015-04-07 2016-04-06 Pharmaceutical compositions for combination therapy

Publications (2)

Publication Number Publication Date
EA201792203A1 true EA201792203A1 (ru) 2018-02-28
EA036757B1 EA036757B1 (ru) 2020-12-17

Family

ID=57072872

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201792203A EA036757B1 (ru) 2015-04-07 2016-04-06 Фармацевтические композиции для комбинированной терапии

Country Status (25)

Country Link
US (1) US10894054B2 (ru)
EP (1) EP3280421B1 (ru)
JP (1) JP6879931B2 (ru)
KR (1) KR20170132879A (ru)
CN (1) CN107613986A (ru)
AR (1) AR104195A1 (ru)
AU (1) AU2016246524B2 (ru)
BR (1) BR112017021311A2 (ru)
CA (1) CA2981507A1 (ru)
CL (2) CL2017002538A1 (ru)
CO (1) CO2017010292A2 (ru)
CR (1) CR20170456A (ru)
EA (1) EA036757B1 (ru)
EC (1) ECSP17073004A (ru)
ES (1) ES2974281T3 (ru)
IL (2) IL254772A0 (ru)
MA (1) MA41083A1 (ru)
MX (1) MX2017012893A (ru)
NI (1) NI201700121A (ru)
PE (1) PE20180034A1 (ru)
SM (1) SMT202400104T1 (ru)
SV (1) SV2017005539A (ru)
TN (1) TN2017000426A1 (ru)
TW (1) TW201642869A (ru)
WO (1) WO2016164413A1 (ru)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9719068B2 (en) 2010-05-06 2017-08-01 Children's Hospital Medical Center Methods and systems for converting precursor cells into intestinal tissues through directed differentiation
EP3149156B1 (en) 2014-05-28 2021-02-17 Children's Hospital Medical Center Methods and systems for converting precursor cells into gastric tissues through directed differentiation
EP3207123A1 (en) 2014-10-17 2017-08-23 Children's Hospital Center D/b/a Cincinnati Children's Hospital Medical Center In vivo model of human small intestine using pluripotent stem cells and methods of making and using same
WO2016144862A1 (en) 2015-03-09 2016-09-15 Intekrin Therapeutics, Inc. Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
EP3445772A2 (en) 2016-04-19 2019-02-27 UREKA Sarl Peptide-oligourea foldamer compounds and methods of their use
ES2929758T3 (es) 2016-05-05 2022-12-01 Childrens Hospital Med Ct Métodos para la fabricación in vitro de tejido del fondo gástrico y composiciones relacionadas con el mismo
SG11201903697WA (en) * 2016-11-04 2019-05-30 Childrens Hospital Med Ct Liver organoid compositions and methods of making and using same
KR102807995B1 (ko) 2016-12-05 2025-05-16 칠드런즈 호스피탈 메디칼 센터 결장 유사장기 및 이를 제조 및 사용하는 방법
JP2020515639A (ja) 2017-04-03 2020-05-28 コヒラス・バイオサイエンシズ・インコーポレイテッド 進行性核上性麻痺の処置のためのＰＰＡＲγアゴニスト
JP7248586B2 (ja) 2017-04-14 2023-03-29 チルドレンズ ホスピタル メディカル センター 複数ドナー幹細胞組成物およびそれを作製する方法
WO2019074793A1 (en) 2017-10-10 2019-04-18 Children's Hospital Medical Center OESOPHAGIAN TISSUE COMPOSITIONS AND / OR ORGANOIDS AND METHODS OF MAKING SAME
WO2019126626A1 (en) 2017-12-21 2019-06-27 Children's Hospital Medical Center Digitalized human organoids and methods of using same
AU2019257632A1 (en) * 2018-04-24 2020-11-26 Ph Pharma Co., Ltd. Use of neutrophil elastase inhibitors in liver disease
AU2019311783A1 (en) 2018-07-26 2021-02-04 Children's Hospital Medical Center Hepato-biliary-pancreatic tissues and methods of making same
GB201812382D0 (en) 2018-07-30 2018-09-12 Nzp Uk Ltd Compounds
JP2021535753A (ja) 2018-09-12 2021-12-23 チルドレンズ ホスピタル メディカル センター 造血幹細胞およびその派生体の生成のためのオルガノイド組成物
WO2020081766A1 (en) * 2018-10-18 2020-04-23 Avolynt Use of sglt2 inhibitors to treat primary sclerosing cholangitis
BR112021009653A2 (pt) 2018-11-20 2021-08-17 Sparrow Pharmaceuticals, Inc. método para administrar um corticosteroide a um paciente em necessidade do mesmo, método para reduzir ou prevenir os efeitos colaterais associados à administração de corticosteroides a um paciente em necessidade do mesmo, e produto farmacêutico
WO2020108830A1 (en) * 2018-11-30 2020-06-04 Ureka Sarl Peptide-oligourea foldamer compounds and methods of their use
JP2022527762A (ja) * 2019-03-26 2022-06-06 インターセプト ファーマシューティカルズ， インコーポレイテッド オベチコール酸を用いた肝疾患の診断および処置の方法
US20220288054A1 (en) * 2019-04-04 2022-09-15 Coherus Biosciences, Inc. Compositions and methods to treat non-alcoholic fatty liver diseases (nafld)
CA3141814A1 (en) 2019-05-31 2020-12-03 Children's Hospital Medical Center Shaped organoid compositions and methods of making same
WO2020243613A1 (en) 2019-05-31 2020-12-03 Children's Hospital Medical Center Methods of generating and expanding hematopoietic stem cells
WO2021029656A1 (ko) * 2019-08-14 2021-02-18 주식회사 바이오톡스텍 하이드로퀴논 유도체, 및 오베티콜릭산을 포함하는 비알콜성 지방간염의 예방 또는 치료용 약학조성물
US20230165853A1 (en) * 2021-01-14 2023-06-01 Enyo Pharma Method for treating chronic kidney diseases
EP4525983A4 (en) 2022-05-16 2025-09-03 Sparrow Pharmaceuticals Inc METHODS AND COMPOSITIONS FOR TREATING GLUCOCORTICOID EXCESS
WO2023225507A1 (en) * 2022-05-16 2023-11-23 Sparrow Pharmaceuticals, Inc. Methods and compositions for treating glucocorticoid excess
AU2023284453A1 (en) * 2022-06-08 2024-12-19 Kojin Therapeutics, Inc. Methods and compositions for initiating, regulating, and modulating weight loss and therapeutic applications thereof
CN120789063B (zh) * 2025-08-15 2026-02-10 北京大学第三医院（北京大学第三临床医学院） 一种药物组合物、制剂及其制备方法和应用

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747445A (en) 1993-06-24 1998-05-05 Astra Aktiebolag Therapeutic preparation for inhalation
US20030109467A1 (en) 2001-11-15 2003-06-12 Isis Pharmaceuticals Inc. Antisense modulation of human FXR expression
WO2000037077A1 (en) 1998-12-23 2000-06-29 Glaxo Group Limited Assays for ligands for nuclear receptors
WO2000040965A1 (en) 1999-01-07 2000-07-13 Tularik, Inc. Fxr receptor-mediated modulation of cholesterol metabolism
US20020132223A1 (en) 1999-03-26 2002-09-19 City Of Hope Methods for modulating activity of the FXR nuclear receptor
CA2368347C (en) 1999-03-29 2007-05-22 F. Hoffmann-La Roche Ag Glucokinase activators
WO2002020463A2 (en) 2000-09-05 2002-03-14 Tularik Inc. Fxr modulators
DK1392714T3 (da) 2001-03-12 2006-01-09 Intercept Pharmaceuticals Inc Steroider som agonister for FXR
ATE381542T1 (de) 2001-08-13 2008-01-15 Phenex Pharmaceuticals Ag Nr1h4-kern-rezeptor-bindende verbindungen
AU2003228485A1 (en) * 2002-04-12 2003-10-27 The University Of Chicago Farnesoid x-activated receptor agonists
AU2004261264A1 (en) 2003-08-01 2005-02-10 Janssen Pharmaceutica N.V. Substituted indazole-O-glucosides
TW200521131A (en) * 2003-08-01 2005-07-01 Janssen Pharmaceutica Nv Substituted fused heterocyclic c-glycosides
EP1568706A1 (en) 2004-02-26 2005-08-31 Intercept Pharmaceuticals, Inc. Novel steroid agonist for FXR
EP2712617B2 (en) 2004-03-12 2020-11-18 Intercept Pharmaceuticals, Inc. Treatment of fibrosis using Fxr ligands
US20060252670A1 (en) * 2004-10-14 2006-11-09 Intercept Pharmaceuticals Inc. Method of reducing drug-induced adverse side effects in a patient
ITMI20050912A1 (it) 2005-05-19 2006-11-20 Erregierre Spa Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici
LT3524261T (lt) 2005-08-19 2024-04-10 Amylin Pharmaceuticals, Llc Eksendino naudojimas diabeto gydymui ir kūno svorio mažinimui
WO2007022518A2 (en) * 2005-08-19 2007-02-22 Amylin Pharmaceuticals, Inc. New uses of glucoregulatory proteins
WO2007076260A2 (en) 2005-12-19 2007-07-05 Smithkline Beecham Corporation Farnesoid x receptor agonists
EP1987051A2 (en) 2006-02-14 2008-11-05 Intercept Pharmaceuticals, Inc. Bile acid derivatives as fxr ligands for the prevention or treatment of fxr-mediated diseases or conditions
AU2007267606A1 (en) 2006-05-24 2007-12-06 Eli Lilly And Company FXR agonists
TW200812982A (en) 2006-05-24 2008-03-16 Lilly Co Eli Compounds and methods for modulating FXR
EP2040713B1 (en) 2006-06-27 2014-06-18 Intercept Pharmaceuticals Inc. Bile acid derivatives as fxr ligands for the prevention or treatment of fxr-mediated deseases or conditions
EP1886685A1 (en) 2006-08-11 2008-02-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods, uses and compositions for modulating replication of hcv through the farnesoid x receptor (fxr) activation or inhibition
EP1894924A1 (en) 2006-08-29 2008-03-05 Phenex Pharmaceuticals AG Heterocyclic FXR binding compounds
EP1894928A1 (en) 2006-08-29 2008-03-05 PheneX Pharmaceuticals AG Heterocyclic fxr binding compounds
EP2121621B1 (en) 2006-12-08 2014-05-07 Exelixis Patent Company LLC Lxr and fxr modulators
US20080300235A1 (en) 2007-06-01 2008-12-04 Wyeth FXR Agonists for Reducing LOX-1 Expression
US20080299118A1 (en) 2007-06-01 2008-12-04 Wyeth FXR Agonists for the Treatment of Malignancies
TW200906823A (en) 2007-07-16 2009-02-16 Lilly Co Eli Compounds and methods for modulating FXR
US8338628B2 (en) 2007-08-28 2012-12-25 City Of Hope Method of synthesizing alkylated bile acid derivatives
US20090163474A1 (en) 2007-10-19 2009-06-25 Wyeth FXR Agonists for the Treatment of Nonalcoholic Fatty Liver and Cholesterol Gallstone Diseases
US20090215748A1 (en) 2007-12-20 2009-08-27 Wyeth FXR agonists for treating vitamin D associated diseases
EP2110374A1 (en) 2008-04-18 2009-10-21 Merck Sante Benzofurane, benzothiophene, benzothiazol derivatives as FXR modulators
US20100056546A1 (en) * 2008-09-04 2010-03-04 Auspex Pharmaceuticals, Inc. Sulfonylurea inhibitors of atp-sensitive potassium channels
CN102639125A (zh) * 2009-05-27 2012-08-15 百时美施贵宝公司 使用sglt2抑制剂及其组合物在对先前用其它抗糖尿病药进行的治疗具有耐受的患者中治疗ii型糖尿病的方法
EP2289883A1 (en) 2009-08-19 2011-03-02 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
KR101822608B1 (ko) * 2010-02-24 2018-01-29 리립사, 인크. 담즙산 격리제로서 사용하기 위한 아민 폴리머
WO2011150286A2 (en) * 2010-05-26 2011-12-01 Satiogen Pharmaceuticals,Inc. Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
WO2011150285A1 (en) 2010-05-26 2011-12-01 Adm Tronics Unlimited Inc. Apparatus and method for uroflowmetry
EP2617514A4 (en) 2010-09-15 2018-01-03 Sumitomo Electric Industries, Ltd. Laser processing method
WO2012106581A1 (en) * 2011-02-03 2012-08-09 The University Of Chicago Fxr inhibitor, bile acid sequestrant as combination therapy for cholesterol reduction
EA201990211A1 (ru) 2012-06-19 2019-06-28 Интерсепт Фармасьютикалз, Инк. Получение, применение и твердые формы обетихолевой кислоты
US9814733B2 (en) * 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
ES2936638T3 (es) 2013-05-14 2023-03-21 Intercept Pharmaceuticals Inc Derivados sustituidos con 11-Hidroxil-6 de ácidos biliares y conjugados de aminoácidos de los mismos como moduladores del receptor X farnesoide
EP4035665A1 (en) 2015-02-06 2022-08-03 Intercept Pharmaceuticals, Inc. Pharmaceutical compositions for combination therapy

Also Published As

Publication number Publication date
US20180117065A1 (en) 2018-05-03
TW201642869A (zh) 2016-12-16
AU2016246524B2 (en) 2021-04-01
JP6879931B2 (ja) 2021-06-02
ES2974281T3 (es) 2024-06-26
MX2017012893A (es) 2018-01-15
CA2981507A1 (en) 2016-10-13
CL2017002538A1 (es) 2018-04-20
MA41083A1 (fr) 2018-05-31
KR20170132879A (ko) 2017-12-04
TN2017000426A1 (en) 2019-04-12
SV2017005539A (es) 2019-01-18
PE20180034A1 (es) 2018-01-09
EP3280421A1 (en) 2018-02-14
CL2018001007A1 (es) 2018-06-15
BR112017021311A2 (pt) 2018-06-26
AU2016246524A1 (en) 2017-10-26
AR104195A1 (es) 2017-07-05
EP3280421B1 (en) 2023-12-27
SMT202400104T1 (it) 2024-05-14
WO2016164413A1 (en) 2016-10-13
CN107613986A (zh) 2018-01-19
NI201700121A (es) 2018-01-10
JP2018510900A (ja) 2018-04-19
ECSP17073004A (es) 2018-02-28
IL254772A0 (en) 2017-12-31
CO2017010292A2 (es) 2018-01-05
IL268316A (en) 2019-09-26
IL268316B (en) 2022-02-01
EA036757B1 (ru) 2020-12-17
CR20170456A (es) 2018-06-13
US10894054B2 (en) 2021-01-19
EP3280421A4 (en) 2019-08-28

Similar Documents

Publication Publication Date Title
EA201792203A1 (ru) Фармацевтические композиции для комбинированной терапии
EA201790568A1 (ru) Применение двойного агониста рецепторов glp-1/глюкагона пролонгированного действия для лечения неалкогольной жировой болезни печени
EA201590759A1 (ru) Композиция для лечения диабета или диажирения, содержащая аналог оксинтомодулина
PH12019501216A1 (en) New compounds as peptidic trigonal glp1/glucagon/gip receptor agonists
EA201300522A1 (ru) Фармацевтические комбинации для лечения метаболических нарушений
EA201890891A1 (ru) Биомаркеры, связанные с заболеваниями, опосредованными интерлейкином-33 (ил-33), и их применение
EA201591839A1 (ru) Терапевтические пептиды
MX2016013244A (es) Derivados de exendina-4 como agonistas peptidicos duales del receptor de glp-1/glucagon.
MX2018000362A (es) Derivados de exendina-4 como agonistas peptidicos duales selectivos de los receptores de glp-1/glucagon.
MX2019006427A (es) Nuevos compuestos como agonistas peptidicos de receptores de glp1/glucagon/gip.
MX2016013248A (es) Agonistas duales del receptor de glp-1/glucagon derivados de exendina-4.
MX2013004406A (es) Tratamiento de diabetes mellitus usando inyecciones de insulina administradas con intervalos variables de inyeccion.
EA200870365A1 (ru) Эндотелин и агонисты рецепторов к эндотелину в лечении заболеваний обмена веществ
EA201891946A1 (ru) Коагонисты глюкагона и glp-1 для лечения ожирения
EA201691420A1 (ru) Композиции енолазы 1 (eno1) и их применение
EA201992272A1 (ru) Ацилированное инсулиновое соединение
EA201591123A1 (ru) Комбинации агониста glp1r и метформина, а также способ их применения при лечении диабета 2 типа и прочих расстройств
EA201992852A1 (ru) Схема дозирования тезетаксела и капецитабина
EA202091744A1 (ru) Лечение аллергического ринита у субъектов детской возрастной категории с применением комбинации мометазона и олопатадина
PE20200889A1 (es) METODOS PARA EL TRATAMIENTO DE ENFERMEDADES RELACIONADAS CON TNF(alfa)
EA201991119A1 (ru) Фармацевтическая композиция, способы лечения и ее применения
UA112502C2 (uk) Спосіб лікування асоційованих шлунково-кишкових захворювань поросят, які супроводжуються діареєю та мультисистемним виснаженням
CL2009000621A1 (es) Uso de un agonista selectivo del receptor s1p1 para preparar un medicamento util en el tratamiento de enfermedades o trastornos asociados con un sistema inmune activado.